The 3rd edition of the Hanson Wade Bacteriophage Therapy Summit will be held as a Digital event from Tuesday 23rd March till Thursday 25th March 2021.
What is the 3rd Bacteriophage Therapy Summit and Why attend?
The overuse of antibiotics has led to the growing problem of multi-resistant bacterial strains, resulting in the inefficiency of antibiotic treatment in many infectious diseases. The use of bacteriophages in a diversity of fields is a topic that has been looked at by many in order to find a solution to the rapid increase of antibiotic resistance. In order to develop a concrete solution to the current situation, the regulatory system must be set accordingly and treatments showing efficacy must be produced.
The 3rd edition of the Bacteriophage Therapy Summit brings together individuals from a diversity of fields for 3 days, translating bacteriophage research into targeted therapeutics demonstrating significant clinical results. Discussions on a range of topics from; characterization, pre-clinical and clinical development, formulation and manufacturing, market delivery, and regulation.
Who will be at the 3rd Bacteriophage Therapy Summit?
Over 20 speakers and more than 60 companies will be attending.
The summit will bring together individuals in positions and occupations of; Presidents, VPs, Managers, C-Level, Scientists, Investigators, Professors, and Associate Professors. Those who work in a diversity of fields such as; drug development, research, NFP, academia, service providers, and consumer brands.
Agenda for the 3rd Bacteriophage Therapy Summit 2021
Tuesday 23rd March 2021
Pre-conference Non-human application focus day
Steven Theriault CEO & CSO at Cytophage – Using Bacteriophages to Prevent Disease in a Large Scale Agricultural setting
Angela Moreno CEO at SciPhage – Exploring Phage-Therapy in the Poultry Industry
Jorge Bardales Co-founder & CSO at Nextbiotics – Enhancing Phage Capacities through a Directed Evolution Platform
Panos Kalatzis Postdoctoral Scholar at University of Copenhagen & Co-founder of Aquatic Biologicals – Going Viral against Bacteria: Implications of using Phage Therapy in Aquaculture
Amit Vikram Senior Research Scientist at Intralytix – Phages for Enhanced Food Safety – An Industry Perspective
Gordon Smith Senior Scientist at Fixed Phage – Controls of Food Spoilage & Food Poisoning Pathogens using Immobilised Bacteriophage
Martin Griessl CEO at Lysando – Artilysin – The Ingenious Way to Control Bacteria
Olivia McAullife Principal Scientist at Teagasc Food Research Centre – Application of Phages in the Food Sector: The Future for Control & Detection of Pathogens?
Chris Lis CTO of Uniphage and Sofia Sigal-Passeck CEO at Uniphage – Systems Learning Approach to Developing Bacteriophage for Usage in Crop Protection
Wednesday 24th March 2021
Michael Koeris Professor of Bioprocessing at Adjunct Faculty, Amgen Bioprocessing Center at Keck Graduate Institute of Applied Life Sciences in Claremont Colleges – Chairperson’s opening remarks & review of the field
Cara Fiore Microbiologist at the FDA, Office of Vaccines Research & Review – Regulatory considerations for Bacteriophage Therapy
Jean-Paul Pirnay Laboratory Manager & Senior Scientist at Queen Astrid Military Hospital – Bringing Phages from the Environment to the Patient: The Experience of the Brussels Military Hospital
Tuval Ben-Yehezkel CEO at Loop Genomics – Single-Molecule Long-Read Sequencing of Phage Mutational Landscape
Minmin Yen CEO at Phage Pro – Democratizing Phage Therapy: Using Phage Therapy to Intervene in Cholera Epidemics
Danish Malik Reader in Industrial Biology at Loughborough University – Using Advanced Metrology tools to Evaluate Phage Aggregation in Liquid Formulations
Bryan Hsu Assistant Professor of Biological Science at Virginia Tech – An Aqueous Based Encapsulation for Oral Delivery
Saima Aslam Associate Professor of Division of Infectious Diseases and Global Public Health at iPATH – Center for Innovative Phage Applications and Therapeutics – Clinical Design Mastermind Session
Clara Leandro Head of Infection at Technophage – Going Into REVERSE: Assessing the Safety of Bacteriophage Treatment in the Management of Diabetic Foot Infections
Mina Pastagia VP of Clinical Development at Armata Pharmaceuticals Inc. – A Review of Armata Pharmaceuticals Clinical Candidates
Yu-Wei Wayne Lin Pharmacometrician at Monash University – Model-Informed Drug Discovery & Development for Bacteriophage Therapy: A Focus on Preclinical Pharmacokinetics & Pharmacodynamics
Pingfeng Yu Research Scientist at Rice University – Hitchhiking Behavior in Bacteriophages: Implications for Phage Therapy and Biofilm Engineering
Thursday 25th March 2021
Carrie-Lynn Langlais Furr Co-founder & CEO at Bacteriophage & Drug Development Consultants LLC – This panel session will feature representatives from a range of phage industries (e.g., human therapy, animal, agriculture, aquatic, food safety, dietary supplements, cosmetics, environment, etc.)
Damon Ellison Chief of Bacteriophage Therapeutics at Walter Reed Army Institute of Research – Development of Fixed Phage Cocktails in the Fight Against Multidrug-Resistant Organisms
Jonathan Kotula Head of Science at Felix Biotechnology – Predicting Phage-Host Interactions
Sailaja Puttagunta CMO at BiomX – Bacteriophage Therapy for IBD
Xavier Duportet Co-founder & CEO at Eligo Bioscience – Using Phages for Gene Therapy of the Microbiome
Lorenzo Corsini Co-CEO at PhagoMed – ɛ2 phages for the treatment of S. aureus infections
Andrew Millard Professor at Leicester University – Engineering of Coliphages
Matthew Dunne Senior Researcher at ETH Zurich, Institute of Food, Nutrition, and Health – Reprogramming Phage Host Ranges through Genetic Engineering
Srivatsan Raman Assistant Professor at University of Wisconsin-Madison – High-Throughput Targeted Genome Engineering to Build Synthetic Therapeutic Bacteriophages
Mark Fitzgerald Partner at Patents Group at Nixon Peabody – Patent Protection for Bacteriophage Therapeutics: Issues & Approaches
Richard Alm Alliance Director at CARB-X, Mark Albrecht Brand Chief of Anti-Bacterial Program at BARDA, Joseph Campbell Program Officer at NIH, and Emily Kramer-Golinkoff Co-founder of Emily’s Entourage – Panel Discussion: How to Attract Private or Public Funding to your research?
View past events by Hanson Wade